ライフサイエンスコーパス: mood stabilizer

1 + mood-stabilizer) or monotherapy (placebo + mood-stabilizer).

2 which if any agents meet this definition of mood stabilizer.

3 four roles included in their definition of a mood stabilizer.

4 ssants was common, often in the absence of a mood stabilizer.

5 r disorder did not include prescription of a mood stabilizer.

6 with an antidepressant in conjunction with a mood stabilizer.

7 iving an antidepressant while treated with a mood stabilizer.

8 and those receiving an antidepressant plus a mood stabilizer.

9 Valproate (VPA) is a commonly prescribed mood stabilizer.

10 rupt/rapid versus gradual discontinuation of mood stabilizer.

11 ertraline, or venlafaxine as an adjunct to a mood stabilizer.

12 thium fulfilled the a priori definition of a mood stabilizer.

13 oate (2-propylpentanoate) is a commonly used mood stabilizer.

14 isorder is a useful tool in conjunction with mood stabilizers.

15 pathway may mediate the antimanic effects of mood stabilizers.

16 s weight gain than commonly used alternative mood stabilizers.

17 raging results when used in conjunction with mood stabilizers.

18 ents with mood disorders who were prescribed mood stabilizers.

19 red combinations of established and putative mood stabilizers.

20 rolled studies of the use of combinations of mood stabilizers.

21 sychoactive drugs such as antipsychotics and mood stabilizers.

22 benefits with antidepressants combined with mood stabilizers.

23 nt role in the actions of antispychotics and mood stabilizers.

24 ith ineffective regimens that do not include mood stabilizers.

25 tion of paliperidone and these two classical mood stabilizers.

26 validated with several clinically effective mood stabilizers.

27 ated pathway and Bcl-2 are major targets for mood stabilizers.

28 and as a therapeutically relevant target for mood stabilizers.

29 th therapeutic effects and were specific for mood stabilizers.

30 ression but happened less in patients taking mood stabilizers (31.6% versus 84.2%).

31 antidepressant medications (14.4% to 48.6%), mood stabilizers (5.3% to 14.5%), stimulants (1.9% to 6.

32 Despite the use of mood stabilizers, a significant proportion of patients w

33 vents provides a potential mechanism whereby mood stabilizers alleviate cerebral morphometric deficit

34 mood stabilizer was more efficacious than a mood stabilizer alone, and as efficacious as haloperidol

35 time to recovery relative to treatment with mood stabilizers alone, and treatment with antidepressan

36 Valproic acid, another mood stabilizer, also increased the number of fluorescen

37 ave themselves been reported to be effective mood stabilizers, although the importance of increased c

38 ve recently reported that the anticonvulsant mood stabilizers (AMS), valproic acid, carbamazepine, an

39 Lithium (Li) is a potent mood stabilizer and displays neuroprotective and neuroge

40 21 is a key mediator of the effects of these mood stabilizers and a potential new therapeutic target

41 ably is involved in mechanisms of actions of mood stabilizers and antidepressants.

42 curring psychiatric conditions, or receiving mood stabilizers and antipsychotics were not included.

43 sts that pharmacological interventions using mood stabilizers and atypical antipsychotics may be effe

44 Mood stabilizers and depressed episode reduced WM FA in

45 K-3beta) may mimic the therapeutic action of mood stabilizers and might therefore allow for the desig

46 Both the control and CT groups received mood stabilizers and regular psychiatric follow-up.

47 ent with antipsychotic, anxiolytic/hypnotic, mood stabilizer, and stimulant medications.

48 otropic medications such as antidepressants, mood stabilizers, antianxiety drugs and opioid antagonis

49 ons can be induced by valproic acid (VPA), a mood-stabilizer, anticonvulsant and histone deacetylase

50 and antidepressants, anxiolytics, hypnotics, mood stabilizers, antipsychotics and treatments for opio

51 Once the mechanisms of the mood stabilizers are identified, it is possible that a m

52 essive illness, and therapeutic mechanism of mood stabilizers are largely unknown.

53 New mood stabilizers are needed that possess efficacy for al

54 nd behavioral consequences to offspring when mood stabilizers are used during pregnancy.

55 ntipsychotic drugs (APD)s and anticonvulsant mood-stabilizers are now frequently used in combination

56 e whether zonisamide, another anticonvulsant mood stabilizer, as well as lithium, a mood stabilizer w

57 subjects with BD taking vs those not taking mood stabilizers, as well as in the left optic radiation

58 Despite important advances in the range of mood stabilizers available, the pharmacological treatmen

59 was partially (atypical APDs) or completely (mood-stabilizers) blocked by the serotonin (5-HT)1A rece

60 only the relative risks of fetal exposure to mood stabilizers but also the high risk of recurrence an

61 e found marginal efficacy for amantadine and mood stabilizers, but found no increased family history

62 tonin reuptake inhibitors, by 98% for use of mood stabilizers, by 171% for use of antipsychotics, and

63 tonin reuptake inhibitors, by 63% for use of mood stabilizers, by 60% for use of antipsychotics, and

64 te initiation in bipolar patients not taking mood stabilizers, careful assessment to rule out bipolar

65 The safest and most efficacious mood stabilizer combinations appear to be the mixtures o

66 There was no increase in prescription of mood stabilizer combinations.

67 up by querying the effect of treatment with mood stabilizers commonly prescribed in bipolar disorder

68 Lithium is a mood stabilizer, dampening both the manic and depressive

69 Mood stabilizers did not prevent cycle acceleration, rap

70 y and are known targets of the anti-suicidal mood stabilizer drug lithium, which increases their expr

71 in the mode of action of antidepressants and mood stabilizer drugs.

72 disorder and the consequences of the use of mood stabilizers during pregnancy, and a consensus docum

73 who continued or discontinued treatment with mood stabilizers during pregnancy.

74 Mood stabilizers (e.g., valproic acid) and antipsychotic

75 Some mood stabilizers, e.g., sodium valproate and carbamazepi

76 Anticonvulsant mood stabilizers, e.g., valproic acid and carbamazepine,

77 Lithium is the most effective mood stabilizer for the treatment of bipolar disorder, b

78 d current substance dependence, treated with mood stabilizers for >or=2 weeks, were randomly assigned

79 m dose=1.7 mg/day, SD=1.3) added to existing mood stabilizers for 6 weeks.

80 cardiovascular disorders, arthritis, and as mood stabilizers for bipolar disorder; however, the mech

81 nd that lithium and valproate, commonly used mood stabilizers for the treatment of manic-depressive i

82 ne, and as efficacious as haloperidol plus a mood stabilizer, for the rapid control of manic symptoms

83 Mood stabilizers have an effect on mitochondrial functio

84 definition by which an agent is considered a mood stabilizer if it has efficacy in treating acute man

85 ipolar course had received prescriptions for mood stabilizers in any follow-up year.

86 A lower level of effectiveness of mood stabilizers in children cannot be ruled out.

87 icle is to review the safety and efficacy of mood stabilizers in combinations.

88 ent and pattern of blood serum monitoring of mood stabilizers in Medicaid patients with bipolar disor

89 ety of risperidone as an adjunctive agent to mood stabilizers in the treatment of acute mania.

90 nical synergism of an APD and anticonvulsant mood-stabilizer in improving the cognitive deficits pres

91 mood disorders, whereas antidepressants and mood stabilizers increase Bcl-2 levels.

92 es despite the prescription of commonly used mood stabilizers, into a CT group or control group.

93 The term "mood stabilizer" is widely used in the context of treati

94 ith infants exposed to another commonly used mood stabilizer, lamotrigine.

95 kin to the antipsychotic haloperidol and the mood stabilizer lithium carbonate.

96 3beta (GSK3beta) inhibitors, especially the mood stabilizer lithium chloride, are also used as neuro

97 to account for the behavioral actions of the mood stabilizer lithium in various animal models of mood

98 Chronic administration of the mood stabilizer lithium returns many of these behavioral

99 ere attenuated by chronic treatment with the mood stabilizer lithium.

100 ctions of the structurally highly dissimilar mood stabilizers lithium and valproate: BAG-1 [BCL-2 (B-

101 citotoxicity, and that co-treatment with the mood stabilizers lithium and valproic acid (VPA) induces

102 urrent manic or mixed episode who received a mood stabilizer (lithium or divalproex) and placebo, ris

103 a typical antipsychotic (perphenazine) and a mood stabilizer (lithium, carbamazepine, or valproate),

104 relationship of adherence to treatment with mood stabilizers (lithium, carbamazepine, and sodium val

105 Current treatments include the so-called "mood stabilizers," lithium and valproic acid.

106 tidepressant treatment in combination with a mood stabilizer may be warranted in some patients with b

107 bits glucocorticoid activation suggests that mood stabilizers may counteract the deleterious effects

108 o have used antianxiety, antidepressant, and mood stabilizer medications, and those with borderline o

109 did not yield higher recovery rates than did mood stabilizer monotherapy.

110 ng older patients with bipolar disorder with mood stabilizers need evidence from age-specific randomi

111 Among patients treated with a concurrent mood stabilizer, no acute change in risk of mania was ob

112 f these patients were receiving a concurrent mood stabilizer or an atypical antipsychotic.

113 ributable to treatment with antidepressants, mood stabilizers or electroconvulsive therapy (ECT).

114 andomized to receive cotherapy (olanzapine + mood-stabilizer) or monotherapy (placebo + mood-stabiliz

115 Because antipsychotic drugs are used as mood stabilizers our studies focused on a newly-marketed

116 Discontinuation of mood stabilizer, particularly abruptly, during pregnancy

117 d 51 of the 187 subjects (27.3%) receiving a mood stabilizer plus a matching placebo (P=0.40).

118 plus adjunctive antidepressant therapy or a mood stabilizer plus a matching placebo, under condition

119 -two of the 179 subjects (23.5%) receiving a mood stabilizer plus adjunctive antidepressant therapy h

120 o receive up to 26 weeks of treatment with a mood stabilizer plus adjunctive antidepressant therapy o

121 ficant trends favoring the group receiving a mood stabilizer plus placebo were observed across the se

122 combination of adequate doses of established mood stabilizers plus at least one antidepressant.

123 administration of lithium, a clinically used mood stabilizer, promoted the proliferation of neuronal

124 addition of an antidepressant to an ongoing mood stabilizer regimen were followed prospectively for

125 idepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have

126 Although the underlying mechanism(s) of this mood stabilizer remains controversial, recent evidence l

127 Consistent with these findings, mood stabilizers such as lithium ion and valproic acid,

128 view will focus on four molecular targets of mood stabilizers that are known to play integral roles i

129 By contrast, for patients taking mood stabilizers, the risk of mania was lower after star

130 der (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more

131 (5-20 mg/d) vs placebo when added to ongoing mood-stabilizer therapy as measured by reductions in You

132 -blind treatment in which in addition to the mood stabilizer they received either continued perphenaz

133 We postulate that mood stabilizer treatment has a profound effect on mitoc

134 ts were euthymic at conception and continued mood stabilizer treatment or discontinued treatment prox

135 mong women who discontinued versus continued mood stabilizer treatment, recurrence risk was twofold g

136 t the effects of antipsychotics when used as mood stabilizer treatment.

137 nd 1376 prescribed quetiapine as maintenance mood stabilizer treatment.

138 77), or quetiapine (n = 1376) as maintenance mood stabilizer treatment.

139 r increase in Cck expression in the VTA with mood stabilizer treatment.

140 , this risk is reduced markedly by continued mood stabilizer treatment.

141 rbidity associated with stopping maintenance mood stabilizer treatment.

142 te, olanzapine, or quetiapine as maintenance mood stabilizer treatment.

143 In contrast, behaviorally effective chronic mood stabilizer treatments in mice inhibit GSK3beta and

144 ntial clinical utility of the anticonvulsant mood stabilizer, valproate, in bipolar disorder with co-

145 d risperidone, as well as the anticonvulsant mood-stabilizers, valproic acid (VPA), zonisamide, and c

146 ider the relative risks of fetal exposure to mood stabilizers versus the high recurrence risks after

147 Risperidone plus a mood stabilizer was more efficacious than a mood stabili

148 The treatment recommendation for adjunctive mood stabilizers was the only recommendation for which c

149 sant medication, as compared with the use of mood stabilizers, was not associated with increased effi

150 For mood stabilizers, whereas carbamazepine and topiramate c

151 Thus, pharmacological interventions such as mood stabilizers, which dampen limbic irritability, or s

152 ession that was inadequately responsive to a mood stabilizer with or without concomitant antidepressa

153 ia (OR, 6.75; 99% CI, 3.52-12.92); 2 or more mood stabilizers, with bipolar disorder (OR, 15.46; 99%

154 lsant mood stabilizer, as well as lithium, a mood stabilizer without anticonvulsant properties, also